MedTrace Logo

Immunogenicity and Safety of Recombinant Zoster Vaccine in People Living With HIV

NCT05898464 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 71

Last updated 2026-04-27

No results posted yet for this study

Summary

The purpose of this study is to compare the immunogenicity and safety of recombinant zoster vaccine according to CD4+ T-cell count and age in people living with HIV, and to provide evidence to guide immunization of people living with HIV.

Conditions

  • Vaccination; Infection
  • Vaccine Adverse Reaction

Interventions

BIOLOGICAL

Recombinant zoster vaccination

Two doses of recombinant zoster vaccine(Shingrix®), 2 months apart

Sponsors & Collaborators

  • National Medical Center, Seoul

    collaborator OTHER

  • SMG-SNU Boramae Medical Center

    collaborator OTHER

  • Seoul National University Hospital

    lead OTHER

Principal Investigators

  • Wan Beom Park, M.D., PhD. · Seoul National University Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-27
Primary Completion
2026-02-10
Completion
2026-02-10

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05898464 on ClinicalTrials.gov